Motilal Oswal initiates coverage on Molbio Diagnostics stock with Buy, sees 21% upside. Here's why

Motilal Oswal has initiated coverage on Molbio Diagnostics, assigning the diagnostics company a Buy rating and setting a target price of ₹1,800.

Brokerage sets ₹1,800 target

The coverage initiation marks Motilal Oswal’s first stated view on Molbio Diagnostics in the provided report. Its target price indicates 21% upside, according to the brokerage call.

The announcement puts the brokerage’s valuation view on Molbio Diagnostics in focus for investors tracking the company’s stock. However, the available details do not include the reasoning behind the rating, financial estimates or any additional risks identified by the brokerage.

What investors know

• Motilal Oswal has initiated coverage on Molbio Diagnostics.
• The brokerage has assigned a Buy rating.
• The target price is ₹1,800.
• The call indicates 21% upside.

Further details on the brokerage’s investment case were not provided in the source information.